PLUS1
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
SMALL CAP PRO
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type | ISIN | Company Description |
|---|---|---|---|---|---|
| Galectin Therapeutics Inc. | GALT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| +0.01 | +0.21% | 4.75 | 4.8 | 4.5 | 4.8 | 4.74 | 20:05:12 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 4.69 | 4.81 | 0.12 | 2.49% | 11 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 930 | 158,663 | $ 4.6913 | $ 744.33k | 284.47k | 3.10 - 9.49 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:46:17 | 25 | $4.75 | USD |
Galectin Therapeutics Inc. Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 195.4M | 41.14M | $ -16.24M | -0.49 | 0.00 | 31.89M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ 0.00 | 0.00% | - | 20.20% |
Galectin Therapeutics Inc. News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/18/2019 | 17:22 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/18/2019 | 17:22 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/18/2019 | 17:22 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/18/2019 | 17:22 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/18/2019 | 17:22 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/18/2019 | 17:21 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/18/2019 | 17:21 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GALT Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Week | 4.46 | 4.96 | 4.4 | 4.6294 | 92k | 234k | 184k | 0.29 | 6.50% |
| 1 Month | 4.15 | 4.96 | 3.17 | 4.0349 | 92k | 691k | 308k | 0.6 | 14.46% |
| 3 Months | 4.35 | 6.1582 | 3.17 | 4.5443 | 59k | 1M | 279k | 0.4 | 9.20% |
| 6 Months | 5.8 | 6.98 | 3.17 | 5.1638 | 59k | 3M | 469k | -1.05 | -18.10% |
| 1 Year | 5.78 | 9.49 | 3.1 | 5.5074 | 59k | 6M | 586k | -1.03 | -17.82% |
| 3 Years | 1.38 | 9.49 | 0.49 | 3.6160 | 13k | 8M | 461k | 3.37 | 244.20% |
| 5 Years | 12.08 | 19.1099 | 0.49 | 4.9253 | 13k | 8M | 393k | -7.33 | -60.68% |
Galectin Therapeutics Inc. Description
| Galectin Therapeutics, Inc. offers drug research & development to create new therapies for fibrotic disease & cancer. It has two compounds in development; one to be used in treatment of liver fibrosis & fatty liver disease & the other in cancer therapy. |
